Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A Sekeres,Larisa Girshova,Vadim A Doronin,Maria Diez-Campelo,David Valcarcel,Suman Kambhampati,Nora-Athina Viniou,Dariusz Woszczyk,Raquel De Paz Arias,Argiris Symeonidis,Achilles Anagnostopoulos,Eduardo Ciliao Munhoz,Uwe Platzbecker,Valeria Santini,Robert J Fram,Ying Yuan,Douglas V Faller,Lionel Ades

doi:10.1182/blood-2021-146154

Abstract

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Full Text